tislelizUMaB in canceR Patients With molEcuLar residuaL Disease
tislelizUMaB in canceR Patients With molEcuLar residuaL Disease
Recruiting · NCT06332274 · Registry updated 2025-05-13Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| tislelizUMaB in canceR Patients With molEcuLar residuaL Disease | Digestive System Diseases, Digestive System Neoplasms, Neoplasms by Histologic Type, Neoplasms by Site, Neoplasms, Connective and Soft Tissue, Thoracic Neoplasms, cancer, colonic disorder, colonic neoplasm, colorectal neoplasm, digestive system disorder, digestive system neoplasm, endocrine system disorder, intestinal disorder, lung cancer, lung disorder, lung neoplasm, malignant endocrine neoplasm, malignant pancreatic neoplasm, neoplasm, pancreas disorder, pancreatic neoplasm, respiratory system disorder, respiratory tract neoplasm, sarcoma | Recruiting | Phase 3 | 2025-05-13 | NCT06332274 |
3 results · Page 1 of 1
Organizations
Swipe the table sideways for more columns.
| Organizations | Linked trials |
|---|---|
| BeiGene | 47 |
| Gustave Roussy, Cancer Campus, Grand Paris | 93 |
| Veracyte, Inc. | 8 |
1 results · Page 1 of 1
Research sites
Swipe the table sideways for more columns.
| Research sites | City | Country | Linked trials |
|---|---|---|---|
| Gustave Roussy | Villejuif | France | 7 |